HCPCS Code Descriptor:
Injection, infliximab-axxq, biosimilar, (avsola), 10 mg
Immunology Anti-TNF Biosimilar
Route of Administration:
Avsola is an Immunology Anti-TNF Biosimilar drug manufactured by Amgen and administered via the Intravenous route of administration. The Q Code: Q5121 is aligned to the drug Avsola.
Avsola works by binding to tumor necrosis factor alpha and preventing it from performing certain processes. Avsola is used to treat a variety of autoimmune disorders. This medication is manufactured by Amgen and is a biosimilar to the medication Remicade (J1745). Avsola was aligned to the HCPCS code Q5121 in July 2020. Patient assistance programs for this medication can be found through the Amgen Safety Net Foundation.
Access Pricing and More By Registering
HCPCS Added Date:
HCPCS Effective Date:
HCPCS Short Description:
Inj. avsola, 10 mg
Billing and Coding Guide: